Subscribe to Search results

At a meeting of the SNBTS directors Dr Gunson reported the agreement to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing.

Published on:

On 7 January 1991, at a meeting of the NBTS/SNBTS Liaison Committee it was reported that no decision had been taken by the Department of Health on the implementation or funding of anti-HCV testing.

Published on:

Professor Cash insisted that HCV testing be discussed.

Published on:

Scotland were under pressure from the SNBTS to fund the introduction of additional virological testing for HCV, but wanted to know what the UK planned to do first.

Published on:

An HCV test would be available towards the end of 1989, but there was a great deal of work to do regarding manufacturing and trials to get to that point.

Published on:

The anticipated commencement date for the Ortho and Abbott 1&2 tests was 1 July 1991.

Published on:

Professor Cash asked for "some idea of the current time schedule to the point of full marketing in the UK for full donation testing."

Published on:

Dr Gunson and Dr Perry had argued that there was already sufficient data for ACVSB to recommend to ministers the introduction of a first-generation Hepatitis C donation screening as soon as possible, but their views were rejected.

Published on:

Professor Cash suggested that the evaluation of second-generation tests might be modified to accommodate the screening programme in Newcastle.

Published on:

Professor Cash noted that Dr Gunson conveyed his concern that the Department of Health had still not decided on a start date, and it now seemed the earliest possible date would be May or June 1991.

Published on:

Dr Mortimer reported on developments in the pilot study, now comparing two further candidate screening tests, from Wellcome and UBI, with results from the Ortho and Abbott test kits.

Published on:

In a minute to Scotland's Deputy Chief Medical Officer Dr Young, Dr McIntyre stated: "Things are moving very fast on the Hepatitis C front" and he anticipated that at the next Advisory Committee on the Virological Safety of Blood meeting it would be decided that "there is no alternative but to recommend the introduction of the test."

Published on:

It was reported in "Blood Bank Week" that Chiron Corporation hoped to have their test to screen blood for non-A non-B Hepatitis available for clinical trials by the end of the year.

Published on:

Dr Gunson produced a paper reporting on the use of the RIBA II confirmatory assay to assess reactive results from the first-generation Ortho and Abbott study.

Published on:

Dr Gunson wrote to regional transfusion directors enclosing an updated report on the comparison study of Abbott and Ortho anti-HCV test kits whilst noting that the study of the new generation tests was proceeding.

Published on:

Professor Tedder tabled a paper on the new generation Abbott and Ortho tests to be discussed at the ninth ACVSB meeting.

Published on:

In "A and Others v National Blood Authority" Mr Justice Burton heard evidence from Dr Harold Gunson, who had been director of the National Blood Transfusion Service and Dr (now Professor) John Barbara, lead scientist in transfusion microbiology at the North London Blood Transfusion Centre at the relevant time, amongst other key factual and expert witnesses.

Published on:

It was generally accepted - and Dr Gunson believed - that the incidence of non-A non-B Hepatitis in the UK was 3%.

Published on:

The incidence of non-A non-B Hepatitis in the US was 7-12%.

Published on:

At the time that the responsible minister was being informed that there was insufficient information to enable a decision to be taken, Australia was introducing routine screening, France was about to introduce it, and it had been in place in Japan since November.

Published on: